

**BRUNO ÉMOND**  
**Vice President**

Direct: 514 394 4455  
Fax: 514 394 4461  
bruno.emond@analysisgroup.com

1190 avenue des Canadiens-de-Montreal  
Tour Deloitte, Suite 1500  
Montreal, Quebec H3B 0G7

Mr. Émond specializes in biostatistics and economics within the field of health economics and outcomes research (HEOR). He has conducted a range of investigations into epidemiology, quality of life, patient-reported outcomes, cost of illness, resource utilization patterns, treatment patterns, cost-effectiveness, and treatment outcomes in the areas of oncology, hepatitis, chronic inflammatory diseases, epilepsy, diabetes mellitus, schizophrenia, cardiovascular diseases, infectious diseases, and hematology. Mr. Émond also has extensive experience performing retrospective database analyses, retrospective medical chart review studies, systematic literature reviews, cost models, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association (APA), International AIDS Society (IAS), American Society of Clinical Oncology (ASCO), and American Society of Hematology (ASH), and published articles in several peer-reviewed journals. Mr. Émond has served as a peer reviewer for *The American Journal of Managed Care*, *CNS Drugs*, and the *Journal of Managed Care & Specialty Pharmacy*, and is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

**EDUCATION**

2016 M.Sc., economics, Université de Sherbrooke, Québec, Canada  
2013 B.Sc., economics, Université de Sherbrooke, Québec, Canada

**PROFESSIONAL EXPERIENCE**

2014–Present Analysis Group, Inc.  
*Vice President (2023–Present)*  
*Manager (2020–2022)*  
*Associate (2015–2019)*  
*Intern (2014–2015)*

2012–2014 Université de Sherbrooke  
*Teaching Assistant in Mathematics and Econometrics*

2011 Richmont Mines Inc.  
*Fall Intern*

2007–2010 Agnico Eagle Mines Limited  
*Summer Intern*

## ARTICLES AND PUBLICATIONS

- Correll CU, Benson C, Emond B, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. *Schizophrenia* (Heidelb). Feb 11 2023;9(1):9.
- Donga P, Emond B, Shah A, et al. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors. *J Comp Eff Res*. Jan 2023;12(1):e220147.
- Narezkina A, Akhter N, Lu X, et al. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. *Clin Lymphoma Myeloma Leuk*. Nov 2022;22(11):e959-e971.
- Liu J, Emond B, Maiese EM, et al. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States. *Curr Med Res Opin*. Nov 2022;38(11):1935-1945.
- McComsey GA, Emond B, Shah A, et al. Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy. *Infect Dis Ther*. Oct 2022;11(5):1883-1899.
- Rogers KA, Lu X, Emond B, et al. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study. *J Manag Care Spec Pharm*. Sep 2022;28(9):1033-1045.
- Wu JJ, Lafeuille MH, Emond B, et al. Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis. *Adv Ther*. Sep 2022;39(9):4157-4168.
- Mesa-Frias M, Rossi C, Emond B, et al. Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases. *J Manag Care Spec Pharm*. Jul 2022;28(7):753-765.
- Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. *Curr Med Res Opin*. Apr 2022;38(4):613-627.
- Emond B, Rossi C, Cote-Sergent A, et al. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bicitgravir/emtricitabine/tenofovir alafenamide in the United States. *Curr Med Res Opin*. Feb 2022;38(2):287-298.
- Vanderpoel J, Stevens AL, Emond B, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. *J Med Econ*. Jan-Dec 2022;25(1):457-468.
- Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States. *J Health Econ Outcomes Res*. 2022;9(1):39-49.
- Leslie LA, Emond B, Lafeuille M-H, Vermette-Laforme M, Lefebvre P, Huang Q. Real-World Treatment Patterns and Healthcare Costs Among Patients with FL with Early Treatment Failure of First-Line Chemoimmunotherapy. *American Health & Drug Benefits*. 2022;15(3):75-85.
- Rogers KA, Emond B, Manceur AM, et al. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. *Curr Med Res Opin*. Aug 2021;37(8):1409-1420.

Ghosh N, Emond B, Lafeuille MH, Cote-Sergent A, Lefebvre P, Huang Q. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study. *Clin Ther*. Aug 2021;43(8):1285-1299.

Emond B, Rossi C, Cote-Sergent A, et al. Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. *J Health Econ Outcomes Res*. Jun 14 2021;8(1):88-98.

Patel C, Emond B, Morrison L, et al. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. *Curr Med Res Opin*. Apr 2021;37(4):665-674.

Fitzgerald T, Melsheimer R, Lafeuille MH, et al. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. *Biologics*. 2021;15:1-15.

Huang Q, Emond B, Lafeuille MH, et al. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. *Curr Med Res Opin*. Dec 2020;36(12):2009-2018.

Chow W, Donga P, Cote-Sergent A, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. *Curr Med Res Opin*. Aug 2020;36(8):1313-1323.

Chow W, Donga P, Cote-Sergent A, et al. Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide. *Patient Prefer Adherence*. 2020;14:2315-2326.

Benson C, Émond B, Lefebvre P, et al. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage. *J Manag Care Spec Pharm*. 2020;26(2):129-141.

Benson C, Émond B, Romdhani H, et al. Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus. *J Manag Care Spec Pharm*. 2020;26(2):117-128.

Émond B, El Khoury AC, Patel C, et al. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. *Curr Med Res Opin*. 2019;35(3):407-416.

Émond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. *Curr Med Res Opin*. 2019;35(10):1751-1759.

Émond B, Joshi K, Khoury ACE, et al. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. *Pharmacoecon Open*. 2019;3(2):177-188.

Dunn K, Lafeuille MH, Jiao X, et al. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV. *J Manag Care Spec Pharm*. 2018;24(10):1040-1051.

Émond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. *Clin Lymphoma Myeloma Leuk*. 2019;19(12):763-775 e762.

- Patel C, Émond B, Lafeuille MH, et al. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. *Drugs Real World Outcomes*. 2019.
- Vergeer M, de Ranitz-Greven WL, Neary MP, et al. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. *Epilepsia Open*. 2019;4(4):581-592.
- Wysham CH, Lefebvre P, Pilon D, et al. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. *J Diabetes Complications*. 2019;33(2):140-147.
- Kamstra R, Pilon D, Lefebvre P, Émond B, Joshi K. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. *Curr Med Res Opin*. 2018;34(8):1377-1388.
- Paller AS, Singh R, Cloutier M, et al. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. *J Drugs Dermatol*. 2018;17(2):187-194.
- Tanton D, Duh MS, Lafeuille MH, et al. Real-world evaluation of HbA<sub>1c</sub>, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. *Curr Med Res Opin*. 2018;34(6):1099-1115.
- Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Émond B, Senbetta M. Economic burden of treatment failure in chronic lymphocytic leukemia patients. *Curr Med Res Opin*. 2018;34(6):1135-1142.
- Wysham CH, Pilon D, Ingham M, et al. HbA<sub>1c</sub> Control and Cost-Effectiveness in Patients with Type 2 Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide 1 Receptor Agonist in a Real-World Setting. *Endocr Pract*. 2018;24(3):273-287.
- Wysham CH, Pilon D, Ingham M, et al. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. *Curr Med Res Opin*. 2018;34(6):1125-1133.
- Joshi K, Lafeuille MH, Brown B, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. *Curr Med Res Opin*. 2017;33(10):1763-1772.
- Pilon D, Behl AS, Ellis LA, Émond B, Lefebvre P, Dawson NA. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. *J Manag Care Spec Pharm*. 2017;23(2):225-235.
- Pilon D, Ellis LA, Behl AS, et al. Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice. *Urology Practice*. 2017;4(3):218-224.
- Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. *Patient Prefer Adherence*. 2017;11:619-629.
- Pilon D, Muser E, Lefebvre P, Kamstra R, Émond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. *BMC Psychiatry*. 2017;17(1):207.
- Pilon D, Tandon N, Lafeuille MH, et al. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. *Clin Ther*. 2017;39(10):1972-1985 e1972.

Wysham CH, Lefebvre P, Pilon D, et al. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. *BMC Endocr Disord*. 2017;17(1):32.

Fontana RJ, Brown RS, Jr., Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. *Liver Transpl*. 2016;22(4):446-458.

Ma E, Bonthapally V, Chawla A, et al. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices. *Clin Lymphoma Myeloma Leuk*. 2016;16(11):625-636 e623.

Xiao Y, Muser E, Fu DJ, et al. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. *Curr Med Res Opin*. 2016;32(4):759-769.

## PRESENTATIONS

“Antipsychotic Medication Guidelines in Patients with Schizophrenia: Real-World Prescribing among Medicaid Beneficiaries,” poster presented at the Academy of Managed Care Pharmacy (AMCP) 2019 Nexus Meeting (October 31, 2019)

“Switching from Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: Real-World Outcomes for Patients with Schizophrenia,” poster presented at the AMCP 2019 Nexus Meeting (October 31, 2019)

“Rapid initiation of antiretroviral treatment (ART) following diagnosis of human immunodeficiency virus (HIV) among Medicaid beneficiaries: a real-world evaluation,” poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting (May 21, 2019)

“Adherence to Antiretrovirals in Medicaid-Insured Patients Living with HIV: Predictors and Economic Consequences,” poster presented at the ISPOR 2018 Annual Meeting (May 23, 2018)

“Incidence of Inflammatory Bowel Disease (IBD) among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors,” poster presented at the AMCP 2018 Annual Meeting (April 25, 2018)

“Efficiency of hockey players in the National Hockey League,” presented at the Société canadienne de science économique 2016 Annual Meeting (May 12, 2016)

## SELECTED HONORS AND AWARDS

2017 Governor General’s Academic Gold Medal  
*Highest grade point average among graduates*

## PROFESSIONAL ASSOCIATIONS AND MEMBERSHIPS

2017–Present International Society for Pharmacoeconomics and Outcomes Research (ISPOR)  
*Member*

**LANGUAGES**

French (native), English (fluent)